Use access key #2 to skip to page content.
$4.84 0.86 (21.61%)
10/13/2008 4:00 PM

Cardiome Pharma Corp. (USA) (CRME)

CAPS Rating:
**

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

View All Commentary (CRME)

Recs

0

Avatar biovestor (20.92) Submitted: 6/30/08 10:26 AM : Outperform Start Price: $8.63 CRME Score: -14.17

Still waiting on FDA ruling for Kynapid, which should be approved plus oral form of the drug with more commercial potential and continued clinical development to move the shares higher.

Report this Post Replies: 0 | Reply

Featured Broker Partners